scispace - formally typeset
B

Barry R. Davis

Researcher at University of Texas at Austin

Publications -  351
Citations -  50989

Barry R. Davis is an academic researcher from University of Texas at Austin. The author has contributed to research in topics: Chlorthalidone & Amlodipine. The author has an hindex of 78, co-authored 342 publications receiving 47899 citations. Previous affiliations of Barry R. Davis include Tulane University & Cardiovascular Institute of the South.

Papers
More filters
Journal ArticleDOI

Selecting Screening Criteria for Clinical Trials: An Example from the Systolic Hypertension in the Elderly Program

TL;DR: The design of a screening procedure for the Systolic Hypertension in the Elderly Program (SHEP), a randomized clinical trial designed to test whether regular administration of antihypertensive medication reduces the risk of stroke in elderly persons with isolated systolic hypertension, is described.
Journal ArticleDOI

Risk of hospitalized gastrointestinal bleeding in persons randomized to diuretic, ACE-inhibitor, or calcium-channel blocker in ALLHAT.

TL;DR: Using administrative databases, the authors re‐examined in a post‐hoc analysis whether the Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial participants randomized to the CCB amlodipine had a greater risk of hospitalized GI bleeding (a prespecified outcome) compared with those randomized toThe diuretic chlorthalidone or the angiotensin‐converting enzyme inhibitor lisinopril.
Journal ArticleDOI

Physical working capacity after acute myocardial infarction in patients with low ejection fraction and effect of captopril.

TL;DR: This study concurs with 2 of 3 previous post-AMI studies and supports the conclusion that working capacity is not affected by angiotensin-converting enzyme inhibition at 4 or 12 months after AMI in patients without congestive heart failure.